Document Detail

Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization.
MedLine Citation:
PMID:  18533739     Owner:  NLM     Status:  MEDLINE    
The immediate goal of reperfusion in acute ST-elevation myocardial infarction (STEMI) is the prompt restoration of myocardial blood flow. Over the past 50 years, numerous advances have been made in achieving this goal by combining pharmacologic regimens with primary percutaneous coronary intervention (PCI) [i.e. pharmacoinvasive recanalizaton]. Fibrinolytics and glycoprotein (GP) IIb/IIIa inhibitors remain the most promising and widely used pharmacologic agents used to date. Early GP IIb/IIIa inhibition in patients undergoing PCI for STEMI results in early reperfusion and can result in improved clinical outcomes. Combination therapy with fibrinolytics and GP IIb/IIIa inhibitors is currently under investigation. The importance of time in the administration of these agents, especially in patients with expected delays to mechanical reperfusion, cannot be overemphasized. Benefits of revascularization are dependent on establishing reperfusion early enough to salvage the myocardium and preserve the left ventricular ejection fraction. As time passes, the effectiveness of treatments decline and patient outcomes are worse. This dependence upon time applies to both fibrinolytic therapy as well as primary PCI. In the current era, primary PCI is the preferred modality for treating patients with STEMI with a goal door-to-balloon time of <90 minutes. However, this modality is not available to all patients presenting with STEMI. Given the importance of time to reperfusion, a pharmacoinvasive approach may be ideal for this patient population. In this paper, we review the literature on pharmacoinvasive recanalization and discuss the optimal combination and timing of these agents. We have linked current American College of Cardiology/American Heart Association Clinical Practice Guidelines to clinical data available in the literature.
Amir Kashani; Robert P Giugliano
Related Documents :
25068019 - Distribution of late gadolinium enhancement in various types of cardiomyopathies: signi...
15800889 - Impact of stents and abciximab on survival from cardiogenic shock treated with percutan...
23062279 - Supramaximal elevation in b-type natriuretic peptide and its n-terminal fragment levels...
22953089 - Takotsubo-like myocardial dysfunction accompanied with cerebellar hemorrhage.
23804879 - Unusual combination of hypoplastic left ventricle, atrioventricular septal defect with ...
24089709 - Epinephrine for prehospital cardiac arrest with non-shockable rhythm.
21900319 - Biomaterial strategies for alleviation of myocardial infarction.
11889969 - Relation of left ventricular hypertrophy to cardiovascular complications in diabetic hy...
24633659 - Geranylgeranylacetone and volatile anesthetic-induced cardiac protection synergism is d...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  8     ISSN:  1175-3277     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2008  
Date Detail:
Created Date:  2008-06-06     Completed Date:  2008-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  187-97     Citation Subset:  IM    
Section of Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary*
Combined Modality Therapy
Controlled Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Therapy, Combination
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Myocardial Infarction / therapy*
Platelet Aggregation Inhibitors / administration & dosage,  therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Time Factors
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Next Document:  Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective stu...